Ankylosing Spondylitis PBMC

Ankylosing Spondylitis PBMC for Immune-Mediated Inflammatory Disease Research

Ankylosing Spondylitis PBMC are isolated from the peripheral blood of IRB-consented donors with a clinically confirmed diagnosis of ankylosing spondylitis, cryopreserved in CryoStor® CS10 and processed within 24 hours of collection. These peripheral blood mononuclear cells give direct access to the lymphocyte populations that define this disease’s immunology, including the Th17 and innate-like T cell compartments.

HLA-B27 and the IL-23/IL-17 Axis

Ankylosing spondylitis is a seronegative immune-mediated inflammatory disease of the axial skeleton, characterised by sacroiliitis, spinal inflammation, enthesitis and pathological new bone formation. It is seronegative in the meaningful sense: there is no disease-defining autoantibody, and the immunology is dominated by genetic HLA association and a cytokine axis rather than by humoral autoimmunity.

• HLA-B27 is the strongest genetic association in ankylosing spondylitis and one of the strongest single-allele associations known in complex disease, though most carriers never develop the condition.
• The IL-23/IL-17 axis is the central effector pathway; the clinical efficacy of IL-17 inhibitors, and of TNF inhibitors, anchors this pathway in validated therapeutic mechanism rather than speculation.
• ERAP1 is a well-replicated susceptibility gene that interacts genetically with HLA-B27, linking antigen peptide trimming to disease risk.
• Th17 cells and IL-17-producing innate-like lymphocytes — including gamma-delta T cells, MAIT cells and group 3 innate lymphoid cells — are enriched or altered in spondyloarthritis and are all resolvable from a PBMC preparation.
• Enthesitis and new bone formation at sites of inflammation distinguish this disease from erosive rheumatoid arthritis, and the immune drivers of that anabolic bone response remain an active question.
• Extra-articular manifestations — acute anterior uveitis, inflammatory bowel disease and psoriasis — cluster with ankylosing spondylitis and support shared-pathway research across the spondyloarthritis spectrum.

Donor Stratification Available

• HLA-B27 status where documented
• Disease activity where documented, including elevated CRP or ESR
• Radiographic ankylosing spondylitis vs non-radiographic axial spondyloarthritis
• Treatment status: NSAID, conventional DMARD, TNF inhibitor, IL-17 inhibitor, JAK inhibitor, or treatment-naive
• Extra-articular involvement: uveitis, inflammatory bowel disease, or psoriasis
• Peripheral arthritis or enthesitis involvement
• Disease duration and age at symptom onset
• Matched healthy controls available

Product Features

• Research Use Only (RUO), cryopreserved PBMCs
• Clinically confirmed ankylosing spondylitis donors
• Available in cell counts ranging from 5 million to 2 billion
• Processed within 24 hours of collection
• Stored using CryoStor® CS10 freezing media
• Viability and recovery reported per lot
• IRB-approved protocols and electronic informed consent
• Screen LeukoLot™ available prior to bulk orders

De-identified Donor Data

• Verified ankylosing spondylitis diagnosis and diagnostic criteria applied
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Treatment history, current regimen and disease activity where documented
• Self-reported allergies and infectious disease history
• Additional ankylosing spondylitis-specific data available upon request

Applications

• Th17 cell frequency, differentiation and IL-17 production assays
• Gamma-delta T cell, MAIT cell and innate lymphoid cell characterisation
• IL-23/IL-17 axis pathway analysis and target validation
• Immunophenotyping of T, B, NK and monocyte populations
• HLA-B27-stratified comparative immune studies
• Single-cell RNA sequencing and TCR repertoire analysis
• Pharmacodynamic profiling of TNF, IL-17 and JAK inhibitor effects on immune cells
• Biomarker discovery for disease activity and treatment response

Other Ankylosing Spondylitis Specimen Types

• Ankylosing Spondylitis Plasma
• Ankylosing Spondylitis Bulk Plasma
• Ankylosing Spondylitis Serum
• Ankylosing Spondylitis Whole Blood
• Ankylosing Spondylitis Leukopak
• Ankylosing Spondylitis Synovial Fluid
• Axial Spondyloarthritis Whole Blood

Compliance and Quality Assurance

• IRB-approved collections and protocols
• 21 CFR Part 11-compliant e-consent system
• HIPAA-compliant donor data protection
• Documentation support available for regulatory review

Ordering & Customization

Ankylosing Spondylitis PBMC samples are shipped on dry ice and available in custom aliquots. For pricing, current availability, international orders or regulatory documentation, contact learnmore@sanguinebio.com. To browse disease-state options and live stock status across our full PBMC inventory, visit our human PBMC page.